Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.73 |
| ▸ | CA1 | P00915 | 6/20 | 0.73 |
| ▸ | CA9 | Q16790 | 6/20 | 0.73 |
| ▸ | CA2 | P00918 | 5/20 | 0.73 |
| ▸ | CA7 | P43166 | 5/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.73 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521670 | 0.87 | CA1 (0.58) | CA12CA1CA9CA2CA7 | |
| SCHEMBL1401499 | 0.87 | CA1 (0.58) | CA12CA1CA9CA2CA7 | |
| Methyl 3,5-Dihydroxybenzoate SCHEMBL38869 | 0.85 | CA1 (1.00) | CA12CA1CA9CA2CA7 | |
| SCHEMBL46504 | 0.85 | CA12 (0.91) | CA12CA1CA9CA2CA7 | |
| SCHEMBL1146888 | 0.83 | CA12 (0.59) | CA12CA1CA9CA2CA7 | |
| SCHEMBL1544732 | 0.80 | HCAR1 (0.53) | CA12CA1CA9CA2CA7 | |
| SCHEMBL1544913 | 0.80 | ATM (0.52) | CA12CA1CA9CA2CA7 | |
| SCHEMBL30822018 | 0.80 | HCAR1 (0.53) | CA12CA1CA9CA2CA7 | |
| SCHEMBL16952776 | 0.80 | KDM4E (0.51) | CA12CA1CA9CA2CA7 | |
| SCHEMBL28444399 | 0.79 | KDM4E (0.51) | CA12CA1CA9CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-04-29 | — | — | US | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-116789636-A | Bifunctional compound, preparation method, pharmaceutical composition and application thereof | 北京康辰药业股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11702426-B2 | Macrocyclic deaza-purinones for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2023-07-18 | — | — | US | disclosed |
| US-11702426-B2 | Macrocyclic deaza-purinones for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2023-07-18 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-04-20 | — | — | US | disclosed |
| EP-2640725-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | Incyte Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130035337-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-07 | — | — | US | disclosed |
| US-20120149682-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| WO-2012068440-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| CN-101679298-A | fused bicyclic heteroaryl derivatives | DAIICHI SANKYO CO LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149682-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CA12 4821/4885CA1 4608/4885CA9 3605/4885 |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | CA12 3102/4885CA1 943/4885CA9 1197/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | CA12 3802/4885CA1 2762/4885CA9 3045/4885 |
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | CA12 3200/4885CA1 3308/4885CA9 193/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CA12 4341/4885CA1 4396/4885CA9 4005/4885 |
| US-11702426-B2 | Macrocyclic deaza-purinones for the treatment of viral infections | DHX15, MAVS, DDX18 | CA12 3772/4885CA1 4804/4885CA9 3012/4885 |
| US-20130035337-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | CA12 3459/4885CA1 4065/4885CA9 2990/4885 |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | CA12 3459/4885CA1 4065/4885CA9 2990/4885 |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | BCL9, BCL9L, BCL3 | CA12 3517/4885CA1 3449/4885CA9 260/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CA12 4341/4885CA1 4396/4885CA9 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.